ARCHIVES

NCI blocked groups from phase III Iressa studies.

This article is from The Cancer Letter archive.

Vol. 30 No. 18 | April 30, 2004

Download PDF Visit The Full Archive

Related Articles

Program Monitors Resistance In Antimicrobial And Antifungal Therapies for Cancer Patients

November 29, 2002

Shortage Of Patients In Right Place, Time Develops As Major Problem For Investigators

May 3, 1974

Pretreatment with Azacitidine Achieves 28-Month Remission

August 30, 2013

XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study

March 25, 2011

Pragmatists vs. Purists: Colon Cancer Screening Guideline Triggers Debate.

October 10, 2008

IOM, NCI Clash Over Proposed Change in Tabulating Minority Research

January 22, 1999